

Joachim G J V Aerts

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/795484/publications.pdf>

Version: 2024-02-01

106
papers

4,305
citations

172207

29
h-index

128067

60
g-index

106
all docs

106
docs citations

106
times ranked

6288
citing authors

#	ARTICLE	IF	CITATIONS
1	Effect of Pembrolizumab After Stereotactic Body Radiotherapy vs Pembrolizumab Alone on Tumor Response in Patients With Advanced Nonâ€“Small Cell Lung Cancer. <i>JAMA Oncology</i> , 2019, 5, 1276.	3.4	670
2	PROCLAIM: Randomized Phase III Trial of Pemetrexed-Cisplatin or Etoposide-Cisplatin Plus Thoracic Radiation Therapy Followed by Consolidation Chemotherapy in Locally Advanced Nonsquamous Nonâ€“Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2016, 34, 953-962.	0.8	365
3	Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): a multicentre, international, randomised, double-blind, placebo-controlled phase 2b trial. <i>Lancet Oncology</i> , The, 2017, 18, 1261-1273.	5.1	356
4	Pembrolizumab with or without radiotherapy for metastatic non-small-cell lung cancer: a pooled analysis of two randomised trials. <i>Lancet Respiratory Medicine</i> , the, 2021, 9, 467-475.	5.2	277
5	Azithromycin maintenance treatment in patients with frequent exacerbations of chronic obstructive pulmonary disease (COLUMBUS): a randomised, double-blind, placebo-controlled trial. <i>Lancet Respiratory Medicine</i> , the, 2014, 2, 361-368.	5.2	226
6	Thyroid Function and Cancer Risk: The Rotterdam Study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2016, 101, 5030-5036.	1.8	96
7	Current State of Dendritic Cell-Based Immunotherapy: Opportunities for in vitro Antigen Loading of Different DC Subsets?. <i>Frontiers in Immunology</i> , 2018, 9, 2804.	2.2	94
8	Home Monitoring in Patients with Idiopathic Pulmonary Fibrosis. A Randomized Controlled Trial. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2020, 202, 393-401.	2.5	79
9	Analyzing high-dimensional cytometry data using FlowSOM. <i>Nature Protocols</i> , 2021, 16, 3775-3801.	5.5	79
10	Tumor mutational load, CD8+ T cells, expression of PD-L1 and HLA class I to guide immunotherapy decisions in NSCLC patients. <i>Cancer Immunology, Immunotherapy</i> , 2020, 69, 771-777.	2.0	70
11	Autologous Dendritic Cells Pulsed with Allogeneic Tumor Cell Lysate in Mesothelioma: From Mouse to Human. <i>Clinical Cancer Research</i> , 2018, 24, 766-776.	3.2	68
12	High-intensity statins are associated with improved clinical activity of PD-1 inhibitors in malignant pleural mesothelioma and advanced non-small cell lung cancer patients. <i>European Journal of Cancer</i> , 2021, 144, 41-48.	1.3	64
13	A prospective cohort study on the pharmacokinetics of nivolumab in metastatic non-small cell lung cancer, melanoma, and renal cell cancer patients. , 2019, 7, 192.		60
14	Clinicopathologic correlates of first-line pembrolizumab effectiveness in patients with advanced NSCLC and a PD-L1 expression of â‰¥50%. <i>Cancer Immunology, Immunotherapy</i> , 2020, 69, 2209-2221.	2.0	60
15	Long-term follow-up of patients with locally advanced non-small cell lung cancer receiving concurrent hypofractionated chemoradiotherapy with or without cetuximab. <i>Radiotherapy and Oncology</i> , 2016, 118, 442-446.	0.3	59
16	Outcomes and resource use of non-small cell lung cancer (NSCLC) patients treated with first-line platinum-based chemotherapy across Europe: FRAME prospective observational study. <i>Lung Cancer</i> , 2015, 88, 215-222.	0.9	58
17	Combination Strategies to Optimize Efficacy of Dendritic Cell-Based Immunotherapy. <i>Frontiers in Immunology</i> , 2018, 9, 2759.	2.2	58
18	Correlation between nivolumab exposure and treatment outcomes in nonâ€“small-cell lung cancer. <i>European Journal of Cancer</i> , 2019, 109, 12-20.	1.3	58

#	ARTICLE	IF	CITATIONS
19	Overt Thyroid Dysfunction and Anti-Thyroid Antibodies Predict Response to Anti-PD-1 Immunotherapy in Cancer Patients. <i>Thyroid</i> , 2020, 30, 966-973.	2.4	57
20	The relation between systemic inflammation and incident cancer in patients with stable cardiovascular disease: a cohort study. <i>European Heart Journal</i> , 2019, 40, 3901-3909.	1.0	54
21	Heterogeneity in Immune Cell Content in Malignant Pleural Mesothelioma. <i>International Journal of Molecular Sciences</i> , 2018, 19, 1041.	1.8	53
22	Immune-related Adverse Events of Pembrolizumab in a Large Real-world Cohort of Patients With NSCLC With a PD-L1 Expression $\geq 50\%$ and Their Relationship With Clinical Outcomes. <i>Clinical Lung Cancer</i> , 2020, 21, 498-508.e2.	1.1	50
23	Association between single-nucleotide polymorphisms and adverse events in nivolumab-treated non-small cell lung cancer patients. <i>British Journal of Cancer</i> , 2018, 118, 1296-1301.	2.9	49
24	Rationally combining immunotherapies to improve efficacy of immune checkpoint blockade in solid tumors. <i>Cytokine and Growth Factor Reviews</i> , 2017, 36, 5-15.	3.2	48
25	Emerging Treatments for Malignant Pleural Mesothelioma: Where Are We Heading?. <i>Frontiers in Oncology</i> , 2020, 10, 343.	1.3	48
26	A multicenter, randomized, phase II/III study of dendritic cells loaded with allogeneic tumor cell lysate (MesoPher) in subjects with mesothelioma as maintenance therapy after chemotherapy: DENDritic cell Immunotherapy for Mesothelioma (DENIM) trial. <i>Translational Lung Cancer Research</i> , 2019, 8, 280-285.	1.3	46
27	Randomized phase II study of pembrolizumab after stereotactic body radiotherapy (SBRT) versus pembrolizumab alone in patients with advanced non-small cell lung cancer: The PEMBRO-RT study. <i>Journal of Clinical Oncology</i> , 2018, 36, 9023-9023.	0.8	46
28	Enhancing Dendritic Cell Therapy in Solid Tumors with Immunomodulating Conventional Treatment. <i>Molecular Therapy - Oncolytics</i> , 2019, 13, 67-81.	2.0	44
29	Collagen Degradation and Formation Are Elevated in Exacerbated COPD Compared With Stable Disease. <i>Chest</i> , 2018, 154, 798-807.	0.4	42
30	Granzyme B is correlated with clinical outcome after PD-1 blockade in patients with stage IV non-small-cell lung cancer. , 2020, 8, e000586.		39
31	Dendritic cell vaccination and CD40-agonist combination therapy licenses T cell-dependent antitumor immunity in a pancreatic carcinoma murine model. , 2020, 8, e000772.		36
32	Efficacy of nivolumab and ipilimumab in patients with malignant pleural mesothelioma is related to a subtype of effector memory cytotoxic T cells: Translational evidence from two clinical trials. <i>EBioMedicine</i> , 2020, 62, 103040.	2.7	35
33	Persistent Health Problems beyond Pulmonary Recovery up to 6 Months after Hospitalization for COVID-19: A Longitudinal Study of Respiratory, Physical, and Psychological Outcomes. <i>Annals of the American Thoracic Society</i> , 2022, 19, 551-561.	1.5	33
34	Induction of Peripheral Effector CD8 T-cell Proliferation by Combination of Paclitaxel, Carboplatin, and Bevacizumab in Non-small Cell Lung Cancer Patients. <i>Clinical Cancer Research</i> , 2019, 25, 2219-2227.	3.2	32
35	Renal Toxicity From Pemetrexed and Pembrolizumab in the Era of Combination Therapy in Patients With Metastatic Nonsquamous Cell NSCLC. <i>Journal of Thoracic Oncology</i> , 2020, 15, 1472-1483.	0.5	32
36	Low-dose cyclophosphamide depletes circulating na^{ve} and activated regulatory T cells in malignant pleural mesothelioma patients synergistically treated with dendritic cell-based immunotherapy. <i>Oncolmmunology</i> , 2018, 7, e1474318.	2.1	30

#	ARTICLE	IF	CITATIONS
37	Nivolumab in pre-treated malignant pleural mesothelioma: real-world data from the Dutch expanded access program. <i>Translational Lung Cancer Research</i> , 2020, 9, 1169-1179.	1.3	30
38	Immunomodulation in cancer. <i>Current Opinion in Pharmacology</i> , 2014, 17, 17-21.	1.7	29
39	Locoregional control and survival after lymph node SBRT in oligometastatic disease. <i>Clinical and Experimental Metastasis</i> , 2018, 35, 625-633.	1.7	28
40	Exhaled breath analysis by use of eNose technology: a novel diagnostic tool for interstitial lung disease. <i>European Respiratory Journal</i> , 2021, 57, 2002042.	3.1	28
41	Blood-based extracellular matrix biomarkers are correlated with clinical outcome after PD-1 inhibition in patients with metastatic melanoma. , 2020, 8, e001193.		28
42	Tremelimumab as second- or third-line treatment of unresectable malignant mesothelioma (MM): Results from the global, double-blind, placebo-controlled DETERMINE study.. <i>Journal of Clinical Oncology</i> , 2016, 34, 8502-8502.	0.8	26
43	Anetumab ravtansine versus vinorelbine in patients with relapsed, mesothelin-positive malignant pleural mesothelioma (ARCS-M): a randomised, open-label phase 2 trial. <i>Lancet Oncology</i> , The, 2022, 23, 540-552.	5.1	25
44	Predictive ability of a drug-based score in patients with advanced nonâ€“small-cell lung cancer receiving first-line immunotherapy. <i>European Journal of Cancer</i> , 2021, 150, 224-231.	1.3	24
45	The Gustave Roussy Immune (GRIm)-Score Variation Is an Early-on-Treatment Biomarker of Outcome in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Treated with First-Line Pembrolizumab. <i>Journal of Clinical Medicine</i> , 2021, 10, 1005.	1.0	23
46	Intratumoral macrophage phenotype and CD8 + T lymphocytes as potential tools to predict local tumor outgrowth at the intervention site in malignant pleural mesothelioma. <i>Lung Cancer</i> , 2015, 88, 332-337.	0.9	22
47	Mutation specific functions of EGFR result in a mutation-specific downstream pathway activation. <i>European Journal of Cancer</i> , 2015, 51, 893-903.	1.3	21
48	Tumour growth rate as a tool for response evaluation during PD-1 treatment for non-small cell lung cancer: a retrospective analysis. <i>ERJ Open Research</i> , 2019, 5, 00179-2019.	1.1	20
49	T cell receptor repertoire characteristics both before and following immunotherapy correlate with clinical response in mesothelioma. , 2020, 8, e000251.		19
50	Post-progression outcomes of NSCLC patients with PD-L1 expression â‰¥ 50% receiving first-line single-agent pembrolizumab in a large multicentre real-world study. <i>European Journal of Cancer</i> , 2021, 148, 24-35.	1.3	19
51	Precision immunotherapy; dynamics in the cellular profile of pleural effusions in malignant mesothelioma patients. <i>Lung Cancer</i> , 2017, 107, 36-40.	0.9	18
52	CO-FLOW: COvid-19 Follow-up care paths and Long-term Outcomes Within the Dutch health care system: study protocol of a multicenter prospective cohort study following patients 2â€™years after hospital discharge. <i>BMC Health Services Research</i> , 2021, 21, 847.	0.9	18
53	Diurnal variation in forced vital capacity in patients with fibrotic interstitial lung disease using home spirometry. <i>ERJ Open Research</i> , 2020, 6, 00054-2020.	1.1	17
54	Malignant Peritoneal Mesothelioma: Patterns of Care and Survival in the Netherlands: A Population-Based Study. <i>Annals of Surgical Oncology</i> , 2019, 26, 4222-4228.	0.7	16

#	ARTICLE	IF	CITATIONS
55	Cisplatin and carboplatin-based chemotherapy in the first-line treatment of non-small cell lung cancer: Analysis from the European FRAME study. <i>Lung Cancer</i> , 2016, 92, 35-40.	0.9	15
56	Potential Molecular Signatures Predictive of Lung Cancer Brain Metastasis. <i>Frontiers in Oncology</i> , 2018, 8, 159.	1.3	15
57	Long-Term Follow-Up of Mesothelioma Patients Treated with Dendritic Cell Therapy in Three Phase I/II Trials. <i>Vaccines</i> , 2021, 9, 525.	2.1	13
58	Immunotherapeutic strategies in non-small-cell lung cancer: the present and the future. <i>Immunotherapy</i> , 2017, 9, 507-520.	1.0	12
59	Randomised phase 3 study of adjuvant chemotherapy with or without nadroparin in patients with completely resected non-small-cell lung cancer: the NVALT-8 study. <i>British Journal of Cancer</i> , 2019, 121, 372-377.	2.9	12
60	Prospective real-world study on the pharmacokinetics of pembrolizumab in patients with solid tumors. , 2021, 9, e002344.		12
61	Fibrotic activity quantified in serum by measurements of type III collagen pro-peptides can be used for prognosis across different solid tumor types. <i>Cellular and Molecular Life Sciences</i> , 2022, 79, 204.	2.4	12
62	Immunotherapy: a new standard of care in thoracic malignancies?. <i>European Respiratory Journal</i> , 2018, 51, 1702072.	3.1	11
63	Adjuvant dendritic cell based immunotherapy (DCBI) after cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) for peritoneal mesothelioma, a phase II single centre open-label clinical trial: rationale and design of the MESOPEC trial. <i>BMJ Open</i> , 2019, 9, e026779.	0.8	11
64	Plasma Predictive Features in Treating EGFR-Mutated Non-Small Cell Lung Cancer. <i>Cancers</i> , 2020, 12, 3179.	1.7	11
65	Immunotherapy in small cell lung cancer: one step at a time: a narrative review. <i>Translational Lung Cancer Research</i> , 2021, 10, 2970-2987.	1.3	11
66	Incidence, treatment and survival of malignant pleural and peritoneal mesothelioma: a population-based study. <i>Thorax</i> , 2022, 77, 1260-1267.	2.7	11
67	Autologous Dendritic Cell Therapy in Mesothelioma Patients Enhances Frequencies of Peripheral CD4 T Cells Expressing HLA-DR, PD-1, or ICOS. <i>Frontiers in Immunology</i> , 2018, 9, 2034.	2.2	10
68	Early Cost Effectiveness of Whole-Genome Sequencing as a Clinical Diagnostic Test for Patients with Inoperable Stage IIIB,C/IV Non-squamous Non-small-Cell Lung Cancer. <i>Pharmacoeconomics</i> , 2021, 39, 1429-1442.	1.7	10
69	Final overall survival (OS) results of the phase III PROCLAIM trial: Pemetrexed (Pem), cisplatin (Cis) or etoposide (Eto), Cis plus thoracic radiation therapy (TRT) followed by consolidation cytotoxic chemotherapy (CTX) in locally advanced nonsquamous non-small cell lung cancer (nsNSCLC).. <i>Journal of Clinical Oncology</i> , 2015, 33, 7506-7506.	0.8	10
70	Iron deficiency anemia as initial presentation of a non-small cell lung carcinoma: A case report. <i>Respiratory Medicine Case Reports</i> , 2015, 16, 109-111.	0.2	9
71	Home monitoring of lung function, symptoms and quality of life after admission with COVID-19 infection: The 'HOMECOMIN' study. <i>Respirology</i> , 2022, 27, 501-509.	1.3	9
72	Prediction of Lifetime and 10-Year Risk of Cancer in Individual Patients With Established Cardiovascular Disease. <i>JACC: CardioOncology</i> , 2020, 2, 400-410.	1.7	8

#	ARTICLE	IF	CITATIONS
73	Do-not-intubate status and COVID-19 mortality in patients admitted to Dutch non-ICU wards. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2021, 40, 2207-2209.	1.3	8
74	Safety of pemetrexed plus platinum in combination with pembrolizumab for metastatic nonsquamous non-small cell lung cancer: A post hoc analysis of KEYNOTE-189. <i>Lung Cancer</i> , 2021, 155, 53-60.	0.9	8
75	IMpower150: Exploratory analysis of brain metastases development.. <i>Journal of Clinical Oncology</i> , 2020, 38, 9587-9587.	0.8	8
76	The clinical impact of <i>Pseudomonas aeruginosa</i> eradication in bronchiectasis in a Dutch referral centre. <i>European Respiratory Journal</i> , 2019, 53, 1802081.	3.1	7
77	Host immune-inflammatory markers to unravel the heterogeneous outcome and assessment of patients with $\geq 50\%$ metastatic non-small cell lung cancer and poor performance status receiving first-line immunotherapy. <i>Thoracic Cancer</i> , 2022, 13, 483-488.	0.8	7
78	Cellular Immunotherapy and Locoregional Administration of CAR T-Cells in Malignant Pleural Mesothelioma. <i>Frontiers in Oncology</i> , 2020, 10, 777.	1.3	6
79	Randomized phase III study of adjuvant chemotherapy with or without low-molecular weight heparin in completely resected non-small cell lung cancer patients: The NVALT-8 study.. <i>Journal of Clinical Oncology</i> , 2016, 34, 8506-8506.	0.8	6
80	Quantification of the tyrosine kinase inhibitor erlotinib in human scalp hair by liquid chromatography-tandem mass spectrometry: Pitfalls for clinical application. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2019, 172, 175-182.	1.4	5
81	A brief report on combination chemotherapy and anti-programmed death (ligand) 1 treatment in small-cell lung cancer: Did we choose the optimal chemotherapy backbone?. <i>European Journal of Cancer</i> , 2020, 137, 40-44.	1.3	5
82	Observed versus modelled lifetime overall survival of targeted therapies and immunotherapies for advanced non-small cell lung cancer patients – A systematic review. <i>Critical Reviews in Oncology/Hematology</i> , 2020, 153, 103035.	2.0	5
83	Statin treatment improves response to anti-PD1 agents in patients with malignant pleural mesothelioma and non-small cell lung cancer.. <i>Journal of Clinical Oncology</i> , 2020, 38, 3074-3074.	0.8	5
84	High familial burden of cancer correlates with improved outcome from immunotherapy in patients with NSCLC independent of somatic DNA damage response gene status. <i>Journal of Hematology and Oncology</i> , 2022, 15, 9.	6.9	5
85	Immunotherapy for mesothelioma: Moving beyond single immune check point inhibition. <i>Lung Cancer</i> , 2022, 165, 91-101.	0.9	5
86	A population-based study describing characteristics, survival and the effect of TKI treatment on patients with EGFR mutated stage IV NSCLC in the Netherlands. <i>European Journal of Cancer</i> , 2022, 165, 195-204.	1.3	5
87	Biomarkers for immune checkpoint inhibitors. <i>Lancet Oncology</i> , The, 2014, 15, e1.	5.1	4
88	Biomarkers in malignant mesothelioma – an unfulfilled need or a waste of resources?. <i>Journal of Thoracic Disease</i> , 2018, 10, S1084-S1087.	0.6	4
89	Blood eosinophil count and GOLD stage predict response to maintenance azithromycin treatment in COPD patients with frequent exacerbations. <i>Respiratory Medicine</i> , 2019, 154, 27-33.	1.3	4
90	Genetic polymorphism in <i>AT1C</i> is associated with effectiveness and toxicity of pemetrexed in non-small-cell lung cancer. <i>Thorax</i> , 2021, 76, 1150-1153.	2.7	4

#	ARTICLE	IF	CITATIONS
91	Blood-based kinase activity profiling: a potential predictor of response to immune checkpoint inhibition in metastatic cancer. , 2020, 8, e001607.		4
92	Molecular data show conserved DNA locations distinguishing lung cancer subtypes and regulation of immune genes. Lung Cancer, 2020, 146, 341-349.	0.9	3
93	Ki67 (MIB-1) as a Prognostic Marker for Clinical Decision Making Before Extended Pleurectomy Decortication in Malignant Pleural Mesothelioma. JTO Clinical and Research Reports, 2021, 2, 100155.	0.6	3
94	The effect of the walk-bike on quality of life and exercise capacity in patients with idiopathic pulmonary fibrosis: a feasibility study. Sarcoidosis Vasculitis and Diffuse Lung Diseases, 2020, 37, 192-202.	0.2	3
95	Experiences of healthcare professionals with support for mesothelioma patients and their relatives: Identified gaps and improvements for care. European Journal of Cancer Care, 2021, 30, e13509.	0.7	2
96	Immune Therapy. Advances in Experimental Medicine and Biology, 2016, 893, 59-90.	0.8	1
97	Re: Comments on "High-intensity statins are associated with improved clinical activity of programmed cell death protein 1 inhibitors in malignant pleural mesothelioma and advanced non-small cell lung cancer patients". European Journal of Cancer, 2021, 153, 267-269.	1.3	1
98	Randomized phase III study of docetaxel versus docetaxel plus intercalated erlotinib in patients with relapsed non-squamous non-small cell lung carcinoma. Lung Cancer, 2021, 160, 44-49.	0.9	1
99	Correlation between nivolumab exposure and treatment outcome in NSCLC.. Journal of Clinical Oncology, 2018, 36, 9057-9057.	0.8	1
100	Pemetrexed (Pem) with pembrolizumab (Pembro) maintenance: A post hoc subgroup safety analysis of KEYNOTE-189.. Journal of Clinical Oncology, 2020, 38, 51-51.	0.8	1
101	Circulating desmosine as a biomarker of azithromycin treatment response: a post hoc analysis of the COLUMBUS randomised controlled trial. ERJ Open Research, 2018, 4, 00136-2018.	1.1	0
102	Influence of Genetic Variation in COMT on Cisplatin-Induced Nephrotoxicity in Cancer Patients. Genes, 2020, 11, 358.	1.0	0
103	Long-term follow up of patients with mesothelioma treated with dendritic cell therapy in three phase I trials.. Journal of Clinical Oncology, 2021, 39, 2618-2618.	0.8	0
104	Retrospective validation of a pretreatment serum protein profile in metastatic non-small cell lung cancer patients treated with a pembrolizumab containing regime as first line of treatment.. Journal of Clinical Oncology, 2021, 39, e21135-e21135.	0.8	0
105	In Response to "Intratumor Distribution of Ki-67 Antigen Beyond Labeling Index for Clinical Decision Making: A New Way of Counting". JTO Clinical and Research Reports, 2021, 2, 100215.	0.6	0
106	Extended interval dosing in patients with cancer receiving immune checkpoint inhibitors: Safety analysis from the EDICI study.. Journal of Clinical Oncology, 2022, 40, 2595-2595.	0.8	0